|
EP2492688A1
|
|
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
WO2011058164A1
|
|
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
WO2009144154A1
|
|
Methods and reagents for predicting clinical outcome and customizing chemotherapy in lung cancer patients
|
|
WO2009144155A1
|
|
Method for prediciting the clinical outcome of patients with non-small-cell lung cancer treated with an anti-metabolite plus an anti-microtubule agent
|
|
EP2123770A1
|
|
Method for determining the DNA repair capacity of a cell
|
|
EP2093566A1
|
|
Method for the prognosis of non-small cell lung cancer
|
|
EP2093568A1
|
|
Brca1 mRNA expression predicts survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy
|
|
EP2093567A1
|
|
Brca1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy
|
|
EP1990423A1
|
|
Method of determining the time to progression of non small cell lung cancer after chemotherapy based on thioredoxin expression
|
|
EP1980627A1
|
|
Method of determining a chemotherapeutic regime and survival expectancy for non small cell lung cancer based on EGFR/CSF-1/CA IX expression
|
|
EP1881079A1
|
|
Method for the detection of EGFR mutations in blood samples
|
|
EP1840224A1
|
|
Method of predicting survival of a non-small-cell lung cancer patient to a chemotherapeutic treatment
|
